Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | ADH1C | P00326 | 1/20 | 0.40 |
| ▸ | ADH1A | P07327 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8418672 | 0.98 | DDB1 (0.46) | DDB1CRBNALDH1A1HRH4HRH3 | |
| SCHEMBL8418673 | 0.98 | DDB1 (0.46) | DDB1CRBNALDH1A1HRH4HRH3 | |
| SCHEMBL2018812 | 0.91 | — | — | |
| SCHEMBL7805428 | 0.84 | ALDH1A1 (0.42) | ALDH1A1HRH4HRH3ADH1CADH1A | |
| SCHEMBL3435014 | 0.84 | DDB1 (0.41) | DDB1CRBNALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL13744502 | 0.83 | DDB1 (0.42) | DDB1CRBNALOX5 | |
| SCHEMBL2305763 | 0.82 | PIK3CD (0.48) | DDB1CRBNALDH1A1POLB | |
| SCHEMBL3436142 | 0.82 | DDB1 (0.45) | DDB1CRBN | |
| SCHEMBL27866405 | 0.80 | KMT2A (0.37) | DDB1CRBNALDH1A1HRH4HRH3 | |
| SCHEMBL12562619 | 0.80 | KDM4E (0.44) | DDB1CRBNALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0714885-B1 | Preparation process of aminoacetamide derivative | EISAI CO LTD (JP) | 1999-09-01 | — | — | EP | claimed |
| EP-0714885-A2 | Preparation process of aminoacetamide derivative | EISAI CHEMICAL CO., LTD. (JP) | 1996-06-05 | — | — | EP | claimed |
| WO-2018072602-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| EP-2663312-B1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20160243102-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2016-08-25 | — | — | US | disclosed |
| US-20150297581-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2015-10-22 | — | — | US | disclosed |
| US-20140357652-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2014-12-04 | — | — | US | disclosed |
| US-8809326-B2 | Isoquinolinone Rho kinase inhibitors | AERIE PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ALCON INC. (CH) | 2008-07-03 | — | — | US | disclosed |
| EP-0714885-B1 | Preparation process of aminoacetamide derivative | EISAI CO LTD (JP) | 1999-09-01 | — | — | EP | disclosed |
| EP-0714885-A2 | Preparation process of aminoacetamide derivative | EISAI CHEMICAL CO., LTD. (JP) | 1996-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243102-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, CIT | DDB1 2760/4885CRBN 3833/4885ALDH1A1 4263/4885 |
| US-20150297581-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, CIT | DDB1 2760/4885CRBN 3833/4885ALDH1A1 4263/4885 |
| US-20140357652-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, CIT | DDB1 2760/4885CRBN 3833/4885ALDH1A1 4263/4885 |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | HSD11B1, HSD17B1, HSD11B2 | DDB1 1580/4885CRBN 4144/4885ALDH1A1 58/4885 |
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ROCK1, ROCK2, ARHGDIA | DDB1 1792/4885CRBN 4299/4885ALDH1A1 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.